Your browser doesn't support javascript.
loading
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks, Didier; de Groot, Jan Willem B; Los, Maartje; Boers, James E; Beerepoot, Laurens V; Polee, Marco B; Beeker, Aart; Portielje, Johanna E A; Goey, Swan H; de Jong, Robert S; Vanhoutvin, Steven A L W; Kuiper, Maria; Sikorska, Karolina; Pluim, Dick; Beijnen, Jos H; Schellens, Jan H M; Grootscholten, Cecile; Tesselaar, Margot E T; Cats, Annemieke.
Afiliação
  • Meulendijks D; Division of Medical Oncology, Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Groot JW; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Los M; Division of Medical Oncology, Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Boers JE; Department of Medical Oncology, Isala, Zwolle, The Netherlands.
  • Beerepoot LV; Department of Internal Medicine, St. Antonius Hospital, Nieuwegein, The Netherlands.
  • Polee MB; Department of Pathology, Isala, Zwolle, The Netherlands.
  • Beeker A; Department of Oncology, St. Elisabeth Hospital, Tilburg, The Netherlands.
  • Portielje JE; Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, The Netherlands.
  • Goey SH; Department of Internal Medicine, Spaarne Hospital, Hoofddorp, The Netherlands.
  • de Jong RS; Department of Medical Oncology, Haga Hospital, The Hague, The Netherlands.
  • Vanhoutvin SA; Department of Internal Medicine, Tweesteden Hospital, Tilburg, The Netherlands.
  • Kuiper M; Department of Internal Medicine, Martini Hospital, Groningen, The Netherlands.
  • Sikorska K; Division of Medical Oncology, Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pluim D; Division of Medical Oncology, Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Beijnen JH; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Schellens JH; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Grootscholten C; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Tesselaar ME; Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
  • Cats A; Division of Medical Oncology, Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Cancer ; 122(9): 1434-43, 2016 05 01.
Article em En | MEDLINE | ID: mdl-26970343
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Gástricas / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Estados Unidos